Keld Fosgerau is an expert in Endocrinology at Society on Sarcopenia, Cachexia and Wasting Disorders (Switzerland). Keld Fosgerau has authored 28 publications, the most recent in 2022. SLR score: 85 (community average: 125). How the SLR is computed.

LeadR Profile

85 ScienceLeadR Reputation 85
Network Map

Endocrinology

Subspecialties:

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 2000 - 2024

Source: PubMed

Society on Sarcopenia, Cachexia and Wasting Disorders

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 28

Citations

Citations: 4 150 1st author: 10 Last author: 3 Unique author: 0


Best Journals

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Lipidated PrRP31 metabolites are long acting dual GPR10 and NPFF2 receptor agonists with potent body weight lowering effect.
PMID 35105898 — neuropeptides, body weight, obesity, natural science disciplines
Sci Rep20228
An Aldehyde Responsive, Cleavable Linker for Glucose Responsive Insulins.
PMID 33169429 — insulin, aldehydes, thiazolidines, hydrazones, insulins
Chemistry202118
Impact of sex on diabetic nephropathy and the renal transcriptome in UNx db/db C57BLKS mice.
PMID 31876119 — genes, diabetic nephropathies, transcriptome, albuminuria, collagen, physiological phenomena, kidney, sex
Physiol Rep201925
Rodent models of diabetic kidney disease: human translatability and preclinical validity.
PMID 32413492 — kidney failure, chronic, kidney diseases, technology, pharmaceutical, therapeutics, diabetic nephropathies, diabetes mellitus, type 2, drug design
Drug Discov Today202010
Novel GLP-1/GLP-2 co-agonists display marked effects on gut volume and improves glycemic control in mice.
PMID 29540315 — diabetes mellitus, glucagon-like peptide 1, eating, psychophysiology, gastric emptying, food, neurophysiology, body weight, glucagon, therapeutics, glucagon-like peptides, glycemic control, diabetes mellitus, type 2
Physiol Behav201838

LeadR Networks

Main global connection map